Skip to content

KOTANIDIS

Active
Private limited company·Activiteiten van medisch specialisten· 5 yrs active
Marche, Avenue de la Toison d'Or 17A ·6900 Marche-en-Famenne, Belgium
KBO/BCE: BE 0760.477.228
Watch Print / PDF
Age5 yrs

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of KOTANIDIS is 0.1% (very low). The 2025 annual accounts show equity of €295k and a net result of €71k. Equity is growing by ~50.3% per year across the filed fiscal years. Its solvency ranks better than 95% of 98 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 5 annual accounts.

Signals

3 signals · with evidence
Strong solvency vs sector
Solvency is in the sector's strongest quartile: better than 95% of 98 peers (2025). A comfortable equity buffer.
View the sector comparison
Consistently profitable
Positive net result in the two most recent financial years (2024 and 2025).
View the result trend
Growing equity
Equity grew over 2023-2025. Profits are largely retained rather than distributed.
View the equity trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide
Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-03-2026, 127 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.
The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
How we compute the deadline
The year end is derived from 5 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.
Deadline per financial year
Year closed Due by Filed Variance Reference
31-12-2025 31-07-2026 26-03-2026 127 d early 2026-00062604
31-12-2024 31-07-2025 11-07-2025 20 d early 2025-00266769
31-12-2023 31-07-2024 26-07-2024 5 d early 2024-00287888
31-12-2022 31-07-2023 27-07-2023 4 d early 2023-00299836
31-12-2021 31-07-2022 19-05-2022 73 d early 2022-20029588

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals
More than 3 years active
Founded in 2020, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.1% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector Young company +Annual accounts: healthy financial profile

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€71k-20.8%
Working capital€228k+0.9%

Annual accounts & ratios

Source: NBB · 2025
Annual accounts filed on 26-03-2026 with the NBB · fiscal year 2025 · volledig
€0€50k€100k€150kOperating result 2021: €42k€42kNet result 2021: €29k€29kOperating result 2022: €42k€42kNet result 2022: €29k€29kOperating result 2023: €97k€97kNet result 2023: €69k€69kOperating result 2024: €127k€127kNet result 2024: €89k€89kOperating result 2025: €100k€100kNet result 2025: €71k€71k20212022202320242025
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Equity: growth of ~50.3%/year over 5 fiscal years, indicative, assuming unchanged policy.
€0€200k€400k€600k2026: €365k (€329k - €400k)2027: €434k (€377k - €490k)2028: €503k (€425k - €580k)2021: €39k2022: €68k2023: €137k2024: €226k2025: €295k20212022202320242025202620272028
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2025 · NACE 86, Human health · compared within the same schema type (full schema)
Metric This company Sector median Position in the sector
Solvency 97.5% 43.6%
better than 95% of 98 sector peers
Net result €71k €49k
better than 58% of 98 sector peers
Equity €295k €111k
better than 68% of 98 sector peers
Gross operating margin €119k €159k
better than 40% of 98 sector peers
Total assets €303k €415k
better than 40% of 98 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P95
2021: P73 · n=1282022: P81 · n=1992023: P89 · n=2262024: P88 · n=2592025: P95 · n=982021 2025
Improving position over 2021-2025 · n=98-259
Net result P58
2021: P46 · n=1282022: P44 · n=1992023: P59 · n=2242024: P67 · n=2582025: P58 · n=982021 2025
Improving position over 2021-2025 · n=98-258
Equity P68
2021: P31 · n=1282022: P42 · n=1992023: P53 · n=2262024: P65 · n=2592025: P68 · n=982021 2025
Improving position over 2021-2025 · n=98-259
Gross operating margin P40
2021: P26 · n=1262022: P25 · n=1962023: P39 · n=2222024: P46 · n=2542025: P40 · n=982021 2025
Improving position over 2021-2025 · n=98-254
Describes the position versus peers, not a forecast.
EBITDA
€113k
-11.3% 21-25
Net profit
€71k
-20.8% 21-25
Cash flow
€83k
-6.8% 21-25
Total assets
€303k
+16.1% 21-25
Equity
€295k
+30.4% 21-25
Working capital
€228k
+0.9% 21-25
Income taxes
€30k
-20.0% 21-25
Dividends
€2k
- 21-25
Show 9 other metrics
Debt
€8k
-78.2% 21-25
Debt ≤ 1y
€8k
-78.2% 21-25
Current ratio
31.36
+315.0% 21-25
Quick ratio
31.36
+315.0% 21-25
Solvency
97.5%
+12.4% 21-25
Debt / equity
0.03
-83.3% 21-25
ROE
23.9%
-39.3% 21-25
ROA
23.3%
-31.8% 21-25
Interest coverage
1402.25
+914.0% 21-25
Figures by fiscal year
Fiscal year2025
Depositvolledig
Revenue-
EBITDA€113k
Net profit€71k
Cash flow€83k
Staff costs-
Income taxes€30k
Dividends€2k
Total assets€303k
Equity€295k
Debt€8k
of which ≤ 1y€8k
of which > 1y-
Working capital€228k
Employees (FTE)-
Ratios (computed)
2025
Current ratio31.36
Quick ratio31.36
Working capital ratio75.2%
Solvency97.5%
Debt / equity0.03
Long-term debt ratio-
Interest coverage1402.25
Gross margin-
Net margin-
ROA23.3%
ROE23.9%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts (23 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€303k
Fixed assets 21/28€68k
Tangible fixed assets 22/27€67k
Financial fixed assets 28€50
Current assets 29/58€235k
Amounts receivable within one year 40/41€2k
Cash & bank 54/58€218k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€303k
Equity 10/15€295k
Contributions / capital 10/11€10k
Reserves 13€284k
Accumulated profits (losses) 14€1k
Amounts payable 17/49€8k
Amounts payable within one year 42/48€8k
Trade debts payable within one year 44€404
Income statement
Gross operating margin 9900€119k
Operating result 9901€100k
Financial income 75€0
Financial charges 65€81
Result before taxes 9903€100k
Income taxes 67/77€30k
Net result for the period 9904€71k
Result to be appropriated 9905€71k
This table shows the latest fiscal year. 4 prior years, with figures and ratios, belong to a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2025 · computed
93 / 100 Excellent
050100
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.

See plans →
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

from the Crossroads Bank
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Marche, Avenue de la Toison d'Or 17A6900 Marche-en-Famenne

Establishment units

1 location
KOTANIDIS
Marche, Avenue de la Toison d'Or 17A, 6900 Marche-en-FamenneActiviteiten van medisch specialisten
since 20212.310.967.689
Physical sites registered in the Crossroads Bank for Enterprises (CBE).

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgian State Gazette · acts

No structured acts for this company yet

That means one of two things: the company has published no company deeds, or its deeds are still queued for reading. The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.

Analysis

Financial profile

5 of 5 axes measured
Health93Profitability100Solvency100Growth78Stability94
93 / 100

Exceptional profile, strong across almost every axis.

All 5 axes are computed from data Checked has read.

Health 93
Profitability 100
Solvency 100
Growth 78
Stability 94

Credit advice

verdict per customer and amount

May this customer buy amount X on invoice? Enter the amount and the payment term. This page computes a GREEN, AMBER or RED verdict from them, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Comparable size, same sector

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Activiteiten van medisch specialisten86220
Primary activity highlighted.
Names & trade names
Legal nameFR KOTANIDIS
Registered office
Marche, Avenue de la Toison d'Or 17A bus 51
6900 Marche-en-Famenne, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.